Ipsen Targets External Innovation With Exicure Option In Rare Neurodegenerative Disorders
Pacts In Huntington's Disease, Angelman Syndrome
France’s Ipsen has taken an exclusive option on two neurodegenerative disease programs at US biotech Exicure, whose oligonucleotide nanoparticles are taken up by many tissues, including the brain.
